Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 11/20 | 0.51 |
| ▸ | GRM5 | P41594 | 10/20 | 0.51 |
| ▸ | ATR | Q13535 | 2/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.45 |
| ▸ | CDK7 | P50613 | 1/20 | 0.44 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.44 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27007742 | 0.98 | GRM1 (0.52) | GRM1GRM5ATRNAMPTPDK4 | |
| SCHEMBL27007840 | 0.94 | GRM1 (0.49) | GRM1GRM5ATRNAMPTPDK4 | |
| SCHEMBL30745984 | 0.93 | CDK9 (0.48) | GRM1GRM5ATRNAMPTPDK4 | |
| SCHEMBL27007939 | 0.93 | CDK9 (0.48) | GRM1GRM5ATRNAMPTPDK4 | |
| SCHEMBL27025947 | 0.92 | GRM1 (0.53) | GRM1GRM5ATRNAMPTPDK4 | |
| SCHEMBL27007897 | 0.90 | CDK9 (0.46) | GRM1GRM5ATRNAMPTPDK4 | |
| SCHEMBL27007998 | 0.87 | GRM1 (0.51) | GRM1GRM5ATRNAMPTPDK4 | |
| SCHEMBL27007867 | 0.87 | SOS1 (0.50) | GRM1GRM5ATRNAMPTPDK4 | |
| SCHEMBL1200092 | 0.87 | GRM1 (0.50) | GRM1GRM5ATRNAMPTPDK4 | |
| SCHEMBL27025939 | 0.86 | NAMPT (0.49) | GRM1GRM5ATRNAMPTPDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018121-A1 | NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE | FOX CHASE CHEMCIAL DIVERSITY CENTER, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018121-A1 | NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE | FOX CHASE CHEMCIAL DIVERSITY CENTER, INC. (US) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018121-A1 | NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE | ERG28, CYP51A1, MANBA | GRM1 2602/4885GRM5 3764/4885ATR 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.